We recently demonstrated that the neurological abnormalities in mouse models of MDS can be reversed by reducing MeCP2 protein levels in the brain using an antisense oligonucleotide (ASO) targeting MECP2 [13, 14]. This evidence concerns the gene MECP2 and myelodysplastic syndrome.